Skip to main content
Premium Trial:

Request an Annual Quote

Transgene, PersonGen Biotherapeutics to Study Oncolytic Virus, Cell Therapy Combo in Solid Tumors

NEW YORK – Transgene and PersonGen Biotherapeutics said on Tuesday that they have teamed up to evaluate Transgene's oncolytic virus therapy combined with PersonGen's CAR T-cell therapy in solid tumors.

The partners will evaluate the feasibility and efficacy of treating solid tumors, such as pancreatic cancer and glioma, using armed oncolytic viruses developed on Transgene's Invir.IO platform and PersonGen's autologous CAR T-cell therapy TAA06.

Within the collaboration, Strasbourg, France-based Transgene will develop new oncolytic virus candidates meant for IV administration in combination with the TAA06 CAR T-cell therapy. Suzhou, China-based PersonGen, meanwhile, will assess whether the combination therapy can eliminate solid tumors in preclinical models.

According to the firms, preclinical work has already shown that after administering PersonGen's CAR T cells, Transgene's oncolytic viruses can selectively replicate and persist in tumor cells, leading to local payload expression. Transgene and PersonGen believe that combining their immunotherapies will allow for local immune responses and tumor lysis and get around the challenges of treating solid tumors with CAR T-cell therapy such as tumor heterogeneity.

PersonGen has already filed an investigational new drug application in China to study TAA06 alone in certain solid tumors and plans to follow suit with US regulators later this year.